An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

This health crisis is largely attributed to sedentary lifestyles, excessive consumption of processed and fast food, and ...

Phase 3 trials of injectable semaglutide have shown it has ... the drug could eventually be approved as a treatment for the fatty liver disease NASH, and as an obesity treatment.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

TUCSON, AZ / ACCESS Newswire / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...